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Abstract
Intercellular communication is fundamental to the survival and maintenance of all multicellular systems, whereas dysregu-
lation of communication pathways can drive cancer progression. Extracellular vesicles (EVs) are mediators of cell-to-cell 
communication that regulate a variety of cellular processes involved in tumor progression. Overexpression of a specific 
plasma membrane enzyme, hyaluronan synthase 3 (HAS3), is one of the factors that can induce EV shedding. HAS3, and 
particularly its product hyaluronan (HA), are carried by EVs and are known to be associated with the tumorigenic prop-
erties of cancer cells. To elucidate the specific effects of cancerous, HAS3-induced EVs on target cells, normal human 
keratinocytes and melanoma cells were treated with EVs derived from GFP-HAS3 expressing metastatic melanoma cells. 
We found that the HA receptor CD44 participated in the regulation of EV binding to target cells. Furthermore, GFP-HAS3-
positive EVs induced HA secretion, proliferation and invasion of target cells. Our results suggest that HAS3-EVs contains 
increased quantities of IHH, which activates the target cell hedgehog signaling cascade and leads to the activation of c-Myc 
and regulation of claspin expression. This signaling of IHH in HAS3-EVs resulted in increased cell proliferation. Claspin 
immunostaining correlated with HA content in human cutaneous melanocytic lesions, supporting our in vitro findings and 
suggesting a reciprocal regulation between claspin expression and HA synthesis. This study shows for the first time that EVs 
originating from HAS3 overexpressing cells carry mitogenic signals that induce proliferation and epithelial-to-mesenchymal 
transition in target cells. The study also identifies a novel feedback regulation between the hedgehog signaling pathway and 
HA metabolism in melanoma, mediated by EVs carrying HA and IHH.
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Introduction
Cancer cells depend on bidirectional communication 
between other cells and the extracellular environment for 
sustained growth, invasion and metastasis. Extracellular 
vesicles (EVs) represent one of the numerous pathways for 
cellular communication [1]. EVs are membrane-enclosed 
particles that are shed from the cell surface, carry bioactive 
molecules [2] and contribute to, for example, the communi-
cation between tumor cells and the extracellular matrix [3]. 
During the past decade, extensive research has demonstrated 
a role for EVs as effective intercellular messengers in can-
cer [4–6]. EVs can stimulate malignant transformation of 
target cells either by paracrine signaling or by fusion and 
internalization with the recipient cells [5]. The importance 
of EVs in cancer progression was first observed in 1980 
when vesicles from highly metastatic melanoma cells (B16 
mouse-F10) enabled poorly metastatic cells (mouse B16-F1) 
to metastasize to the lungs [7].
EVs are secreted from cells through different mecha-
nisms including (1) exocytosis of multivesicular bodies via 
fusion with the plasma membrane, (2) direct budding from 
the plasma membrane, and (3) via the tips of filopodia or 
other plasma membrane protrusions [8]. We have previ-
ously shown that overexpression of HAS3 triggers growth 
of filopodia [9], which enhances EV shedding [10]. Hyalu-
ronan synthases (HAS1-3) are plasma membrane enzymes 
responsible for the synthesis of hyaluronan (HA), which is 
involved in numerous cellular functions, such as prolifera-
tion and adhesion [11, 12]. Expression of HAS2 [13] and 
HAS3 [14, 15] are associated with malignant transformation 
and aggressive tumor growth. However, the specific features 
of HAS3-induced EVs and their role in cancer progression 
have yet to be studied.
Enhanced proliferation, accompanied by altered activity 
and expression of cell cycle proteins, is one of the hallmarks 
of cancer cells [16]. The commitment to a new round of cell 
division (G1/S phase) is the point where cell cycle molecules 
are altered in cancer cells enabling uncontrolled prolifera-
tion [17]. c-Myc is one of the prominent proto-oncogenes. 
When deregulated it enables oncogenic potential by pro-
moting uncontrolled cell cycle and proliferation by directly 
regulating the cyclin-dependent kinases (CDKs) [18, 19]. 
Selective dependence on interphase CDKs explains the 
increased rounds of division in tumor cells [20]. c-Myc’s 
involvement in proliferation is reflected by its action in regu-
lating growth-promoting genes [21] and CDK4 [19, 22].
Claspin is a nuclear protein involved in DNA replica-
tion and cellular homeostasis [23]. Expression of claspin in 
normal cells is hardly detectable at the G0/G1 phase, while 
it spikes at the S/G2 phase and drops during mitosis [24]. 
Claspin has a dual role in DNA replication; it can either pro-
mote or inhibit the process, depending on the circumstances. 
For example, while claspin initiates DNA replication dur-
ing the G1/S phase, it can also inhibit DNA replication and 
thereby cell proliferation during DNA damage and repair. 
Claspin protein level directly corresponds to an increased 
or decreased proliferation rate [24, 25]. Apart from being an 
upstream regulator of claspin, c-Myc itself can also be regu-
lated by numerous signal transduction pathways like hedge-
hog, Wnt, Notch, IGF and NFкB [21]. Constitutive activa-
tion of these pathways in cancer facilitates over-expression 
of c-Myc, as the cell traverses through cell cycle progression 
[16, 21].
Here we focus on hedgehog signaling (HH), a conserved 
pathway that plays an important role in embryonic develop-
ment and in the progression of numerous cancers [26–28]. 
Binding of HH ligands such as Indian hedgehog (IHH), 
desert hedgehog (DHH) and sonic hedgehog (SHH) to the 
smoothened, frizzled class receptor (Smo) stimulates HH 
signaling and a cascade of downstream intracellular events 
that regulates cell survival, proliferation and differentiation 
[29]. It has been shown that HH ligands can be carried via 
EVs [30, 31]. In this study, we treated normal keratinocytes 
and melanoma cells with EVs originating from metastatic 
melanoma cells overexpressing GFP-HAS3 and investi-
gated their possible effects on the target cell properties. We 
observed that GFP-HAS3 EVs carried IHH, HAS3, EGF, 
EGFR and CD44. Moreover, IHH in HAS3-EVs activated 
the HH signaling pathway, which subsequently triggered 
c-Myc activation, cell proliferation and epithelial-to-mes-
enchymal transition. c-Myc-induced proliferation of target 
cells was mediated by the regulation of claspin. This study 
shows for the first time that EVs originating from HAS3 
overexpressing cells carry mitogenic signals that induce sus-
tained proliferation and EMT in target cells.
Results
Characterization of EVs secreted by MV3 human 
metastatic melanoma cells
EVs were isolated from MV3 human melanoma cells sta-
bly expressing GFP-HAS3, which has been characterized 
previously [32, 33]. To trap the GFP-HAS3-positive EVs 
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for visualization in situ we cultured the MV3 cells in type I 
collagen matrix. Live GFP-HAS3 expressing cells are grown 
inside a 3D gel of type I collagen matrix showed a high num-
ber of GFP-HAS3-positive filopodia and EVs shedding into 
the surrounding matrix (Fig. 1a). EVs shed from GFP-HAS3 
expressing MV3 cells were termed as HAS3-EVs. Immu-
nostaining of the 3D cultures demonstrated that both doxy-
cycline-induced and uninduced cells secreted CD44-positive 
EVs (arrows in Fig. 1b, c), and most of the HAS3-EVs dis-
played an association with CD44 immunostaining (Fig. 1d). 
The HA-positivity of HAS3-EVs was analyzed in isolated 
EV preparations with confocal microscopy (Fig. 1e–h). 
Staining with the HA probe, fluorescently labelled HA bind-
ing complex (fHABC), indicated that EVs of different sizes 
were coated with HA (arrows in Fig. 1h). HAS3-EVs carried 
GFP-HAS3, while uninduced cells with native-EVs (here-
after termed as MV3-EVs) were negative, as indicated with 
GFP immunostaining (Fig. 1i). EVs from both the induced 
and uninduced cells carried the HA receptor, CD44 and EV 
markers, such as CD81 and CD63, as well as actin (Fig. 1i). 
To analyze the EV secretion from these cells, we utilized 
NTA analysis, which showed a 75% increase in the total 
particle counts in the HAS3-EVs group, compared to MV3-
EVs (Fig. 1k). No difference was detected in the size dis-
tribution between MV3- and HAS3-EVs, and their average 
diameter was 150 nm (Fig. 1l). TEM analysis of isolated 
preparations confirmed a typical structure of EVs (Fig. 1j). 
The EV secretion and size distribution were tested in one 
more melanoma cell line, C8161 with doxycycline induced 
GFP-HAS3. EVs from uninduced cells will be addressed 
as C8161-EVs while the EVs from induced cells will be 
addressed as C8161 HAS3-EVs. The NTA analysis revealed 
a 58% increase in the total particle counts in C8161-HAS3 
EVs group compared to C8161-EVs (Suppl. Figure 2a) 
while the size distribution between the two groups remained 
unchanged (Suppl. Figure 2b).
Binding of HAS3‑EVs to target cells and their effect 
on HA secretion, proliferation and invasion
When a normal keratinocyte cell line, HaCaT, was treated 
with both EVs and HA oligomers of different lengths (HA6, 
HA8, HA10) (Suppl. Figure 1j, k), binding of EVs to the 
cell surface significantly decreased (Fig. 2a). HA oligomers 
are known to inhibit HA and CD44 interaction [34] and this 
showed that CD44 is one of the potential binding partners 
aiding in EV interaction with the cells. Treating HaCaT cells 
with HAS3-EVs increased HA secretion levels of the cells 
when compared to cells that were treated with MV3-EVs 
(Fig. 2b). Since increased cell proliferation is one of the 
earlier traits in cancer progression, we analyzed the effect 
of MV3- and HAS3-EVs on the proliferation rate of HaCaT 
and WM115, a primary melanoma cell line. Over a period 
of 4 days, both HaCaT (Fig. 2c) and WM115 (Fig. 2d) pro-
liferation was significantly increased with MV3-EVs treat-
ment, with a relatively higher rate in HAS3-EVs treatment. 
The proliferation rate of HaCaT cells when treated with EVs 
from a different melanoma cell line, C8161-GFP-HAS3 was 
observed to follow the same pattern. HaCaT cells treated 
with C8161 HAS3-EVs had significantly higher prolifera-
tion rate on day 4, compared to cells treated with C8161-
EVs (Suppl. Figure 2c). We also assessed if the same trend 
was observed in cells invasion, after EV treatment using 
type I collagen as the matrix. While there was no significant 
change in the invasion of HaCaT cells (Fig. 2e), both MV3- 
and HAS3-EVs treatment-induced invasion in WM115 cells, 
with HAS3-EVs giving a statistically significant increase 
(Fig. 2f). The results showed that HAS3-EVs can promote 
oncogenic properties in the target cells, such as prolifera-
tion and invasion. Next, we investigated which factors could 
influence these changes.
Downstream effects and key players of HAS3‑EVs 
in target cells
Due to the increase in cell proliferation after MV3- and 
HAS3-EVs treatment, we next analyzed changes in cell 
cycle proteins using an antibody array to target 60 key pro-
teins relevant for cell proliferation. Interestingly, HAS3-EVs 
treatment induced an increased level of proteins such as cyc-
lin E, E2F1, E2F2, CDK1, Ki97 and cullin-3, which are 
involved in DNA transcription and cell division (Fig. 3a). 
These results gave the intriguing indication that EVs treat-
ment causes changes in the cell proliferation rate, which 
prompted us to employ complementary high-throughput 
RNA sequencing and label-free quantitative proteomic 
techniques to identify key role players. From whole cell 
lysates of HaCaT treated with or without MV3- and HAS3-
EVs, differentially expressed proteins were analyzed using 
quantitative proteomics. Pathway analysis was performed 
using IPA software, comparing MV3- and HAS3-EVs treat-
ments with the untreated control (Fig. 3b; Suppl. Table 1). 
The top-ranked pathways included rearranged cytoskeleton, 
increased cell proliferation and remodeled epithelial adhe-
rens junctions, all of which were positively associated with 
the HAS3-EVs group, and to a lesser extent with MV3-EVs 
(Fig. 3b). This expression pattern shows that EVs have an 
impact on various processes in the cells promoting them 
towards uncontrolled proliferation and possibly EMT. Over-
all, from both protein array and mass spectrometry analy-
ses, we could discern that E2F signaling and levels of other 
regulatory proteins involved in cell cycle progression were 
increased upon HAS3-EVs treatment.
Next, we wanted to identify the key driving factors 
through which HAS3-EVs affect these cellular processes. 
Using Western blotting, we compared the levels of c-Myc, 
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Fig. 1  Characterization of EVs secreted by MV3 human metastatic 
melanoma cancer cells with stable, inducible expression of GFP-
HAS3. a 3D projection of live GFP-HAS3 expressing cell grown in 
3D collagen gel. Confocal sections of CD44-immunostained unin-
duced (b) and induced (c) MV3 cells and a higher magnification 
image of an area indicated by a white box in (c) is shown in (d). 
Panels e–h show HA staining of EV preparations isolated from GFP-
HAS3 expressing cells, and h shows a higher magnification image of 
the area indicated by a black box in (g). i Western blotting of GFP-
HAS3 detected with GFP antibody and other typical EV markers. 
Nanoparticle tracking analysis of EV levels (j) and size distribution 
(k) secreted from uninduced (MV3-EVs) and induced (HAS3-EVs) 
MV3 cells, and l transmission electron microscopy of EVs isolated 
from GFP-HAS3 expressing cells. Data represent mean ± S.E. from 
three independent experiments; *P < 0.05 (one-way ANOVA, Tukey’s 
test). Arrows in all panels indicate EVs. Scale bars represent 20 µm in 
(c), 2 µm in (d) and (h), 10 µm in (g) and 200 nm in (j)
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NFκB-p65, CD44, EGFR and MAPK, which are involved 
in HA signaling and cell proliferation [35–39], in HaCaT 
cells treated with or without MV3- and HAS3-EVs. Fur-
thermore, the levels of EMT markers such as E-cadherin 
and Slug were also analyzed (Suppl. Figure 1c). Although 
we could observe changes in many of the oncogenic and 
signaling proteins promoting cell proliferation, an increase 
in c-Myc expression in the HAS3-EVs group was profound 
and statistically significant. Additionally, the whole-cell 
proteome analysis of HaCaT cells showed claspin (Swiss-
Prot ID: Q9HAW4, Suppl. Table 1) as one of the top hits in 
HAS3-EVs treatment. Claspin expression was significantly 
increased with HAS3-EVs (1.95-fold change) but not with 
MV3-EVs (0.86-fold change) (Suppl. Table 1). Thus, claspin 
could be one of the differentially expressed proteins between 
MV3- and HAS3-EVs treatment and we were interested to 
understand its role in HAS3-EVs induced cell proliferation. 
Involvement of claspin in cell cycle progression was also 
highlighted in the network analysis of the extracted pro-
teome (CLSPN in Suppl. Figure 3). Interestingly, our RNA 
sequencing analysis showed that HaCaT cells treated with 
HAS3-EVs exhibited an enrichment of hedgehog signaling 
(HH) pathway genes such as GLI1 and PTCH1 when com-
pared to untreated control and MV3-EVs treatment (Fig. 3c). 
Based on the above-described results, significantly elevated 
protein expression of claspin and mRNA levels of GLI1 and 
PTCH1 pinpoints that hedgehog signaling and claspin could 
be involved in HAS3-EVs mediated increased cell prolifera-
tion. Though not directly shown in our mass spectrometry or 
RNA-sequencing analyses, differential expression of c-Myc 
was observed with HAS3-EVs treatment with Western blot-
ting. We could not find commonly affected key players in 
mRNA and protein expression in the treated HaCaT cells, 
thus differentially expressed targets that were related to cell 
Fig. 2  Binding of HAS3-EVs 
and their effect on target cell 
HA secretion, proliferation and 
invasion. a Effect of short HA 
oligosaccharides (6–10 mono-
saccharide units) on binding of 
EVs originating from HAS3-
induced MV3 cells to HaCaT 
cells. b Effect of melanoma cell-
derived EV treatment on HA 
secretion levels of HaCaT cells. 
HA secretion was quantified and 
normalized to RNA content of 
the cells. Effect of melanoma-
derived EVs on the proliferation 
rate (c, d) and invasion (e, f) in 
HaCaT (c, e) and WM115 (d, 
f) cells, respectively. The data 
represent mean ± S.E. of four 
independent experiments. *P 
value < 0.05, **P value < 0.01, 
one-way ANOVA (Tukey’s test)
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proliferation were sorted out to characterize them further in 
our in vitro experiments. Therefore, we analyzed the possi-
ble connection between hedgehog signaling with c-Myc and 
claspin in HAS3-EVs mediated increase in cell proliferation.
HAS3‑EVs act through c‑Myc and claspin in target 
cells to regulate proliferation
It has been previously reported that c-Myc and claspin regu-
late cell proliferation [24, 40] but their association with HH 
signaling and melanoma progression is largely unknown. 
Therefore, we studied the role of c-Myc and claspin on 
HaCaT and WM115 cell proliferation by siRNA-mediated 
knockdown. When treated with HAS3-EVs, c-Myc and 
claspin protein levels were significantly elevated, in both 
HaCaT (Fig. 4a, c, d) and WM115 cells (Fig. 4b, f, g). 
MV3-EVs treatment in both the cell types only led to minor 
changes in the expression of these proteins. Knocking down 
c-Myc and claspin with siRNAs significantly decreased their 
expression, while adding HAS3-EVs partially rescued it 
(Fig. 4a–d, f–g). Although knocking down c-Myc decreased 
the levels of claspin, the reciprocal effect was not observed. 
These results indicate that claspin expression was dependent 
on c-Myc activation for its expression while c-Myc protein 
expression was claspin-independent. Furthermore, HAS3-
EVs had a direct role in c-Myc and claspin activation. Since 
c-Myc [21] and claspin [24] play a role in cell proliferation, 
we next studied the change in cell number 48 h post siRNA 
transfection. HAS3-EVs treated cells exhibited a higher pro-
liferation rate compared to control cells (Fig. 4e, h). Also, 
HAS3-EVs treated cells with claspin and c-Myc knockdown 
showed a significantly lower proliferation rate (Fig. 4e, h). 
These results demonstrate that the increase in proliferation 
mediated by HAS3-EVs acted through c-Myc and claspin. 
Next, we aimed to resolve the specific activation mechanism 
of c-Myc by HAS3-EVs.
HAS3‑EVs induce c‑Myc and EMT via HH signaling
Since HH signaling was enhanced by HAS3-EVs treatment 
(Fig. 3c), we investigated the direct effect of HH pathway 
members on c-Myc activation. To this end, the central HH 
pathway transcription factors, Gli-1 and -2 were targeted 
using a specific inhibitor called GANT58 [41]. Further-
more, the protein levels of Gli-1 and -2, along with claspin, 
c-Myc and EMT regulators such as slug and E-cadherin, 
were analyzed with Western blotting. Constitutively over-
expressing c-Myc with a point mutation T58A activates its 
oncogenic functions and diminishes its ability to accelerate 
apoptosis [42, 43]. T58A mutation has also increased c-Myc 
protein stability to twofold [44]. We wanted to see whether 
Gli inhibition has any effect on c-Myc regulation of claspin 
and increased cell proliferation. To test it, we used consti-
tutively activated c-Myc T58A, thus checking whether the 
mutant could reverse the effects of Gli inhibition. HaCaT 
(Fig. 5a, c, e) and WM115 cells (Fig. 5b, d, f) treated with 
HAS3-EVs showed an increase in Gli-1 and -2, c-Myc and 
claspin protein levels. Gli inhibitor effectively reversed the 
effect of HAS3-EVs by decreasing the expression of Gli-1 
and -2, c-Myc and claspin. Moreover, c-Myc T58A but not 
mock transfection partially rescued the effect of HAS3-EVs 
on these protein levels (Fig. 5a–f). We also measured the 
proliferation rate as an end result of these treatments; the Gli 
inhibitor with or without HAS3-EVs decreased the prolifera-
tion, while c-Myc T58A treatment along with HAS3-EVs 
increased proliferation similar to control cells (Fig. 5g, h). 
These results suggest that HH signaling induced by HAS3-
EVs activates c-Myc and claspin to regulate cell prolifera-
tion. In addition to enhanced proliferation rate, EMT is also 
a hallmark for cancer. We, therefore, studied an epithelial 
marker (E-cadherin) and mesenchymal marker (slug), to 
map out the extent of HAS3-EV treatment. As it can be seen 
from the results, HAS3-EVs treatment decreased E-cad-
herin (Fig. 5a, d) and increased slug levels (Fig. 5 a, d, b, f) 
(Suppl. Figure 1b–i). WM115 did not express E-cadherin 
endogenously. The results thus illustrate that HH signaling 
from HAS3-EVs is responsible for the increased prolifera-
tion rate and EMT via activation of c-Myc.
IHH is the specific factor for HAS3‑EV mediated 
c‑Myc activation and claspin correlates with HA 
in human cutaneous melanocytic lesions
Next, we wanted to identify which mitogen was responsi-
ble for the activation of the HH pathway and how it was 
associated with HAS3-EVs. There are three principal HH 
ligands—IHH, DHH and SHH, all of which act through Gli 
proteins [3]. Using doxycycline inducible GFP-HAS3 over-
expressing MV3 cells, we analyzed the expression of HH 
genes by qPCR. Among the different genes that were tested, 
IHH, DHH, GLI1, PTCH1 and SMO expression were sig-
nificantly increased in MV3 cells with GFP-HAS3 overex-
pression (Fig. 6a). This observation gave additional support 
to our RNA sequencing results, where we identified GLI1 
Fig. 3  Downstream effects and keys players of HAS3-EVs in target 
cells. a Antibody array analysis showing the cell cycle protein expres-
sion of HaCaT cells, treated with HAS3-EVs compared to untreated 
control. The protein expression values of HaCaT cells treated with 
HAS3-EVs were charted based on fold change compared to untreated 
control. Six replicates of each protein on the array (FC fold change), 
b Differentially enriched canonical pathways of HaCaT cells pro-
teome shared amid groups treated with MV3-EVs and HAS3-EVs, 
as compared to control. Arrow heads point to pathway activation 
(z-score > 2) or inhibition (z-score < -2), as predicted by IPA algo-
rithms. c A heat map of row-wise scaled group mean mRNA expres-
sion of control HaCaT cells or cells treated with MV3- or HAS3-EVs 
(N = 3 per group) for genes involved in hedgehog signaling
◂
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Fig. 4  HAS3-EVs act through c-Myc and claspin in target cells to 
regulate proliferation. Western blots showing the expression of c-Myc 
and claspin in EVs- and siRNA-treated cells in HaCaT (a, c, d) and 
WM115 (b, f, g). Cell proliferation rate of HaCaT (e) and WM115 
(h) cells with EVs- and siRNA-treatments. The statistical signifi-
cance tests were done in comparison to control. The data represent 
mean ± S.E. of four independent experiments. *P value < 0.05, **P 
value < 0.01, ***P value < 0.001, one-way ANOVA (Tukey’s test). C 
control, Ci control siRNA (scrambled siRNA), H3 or H3-EVs HAS3-
EVs, Clsi and Myci siRNAs for claspin and c-Myc
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Fig. 5  HAS3-EVs induce c-Myc and EMT by HH signaling. Pro-
tein expression of HH and EMT markers were tested in HaCaT (a, 
c, e) and WM115 cells (b, d, f). Both HaCaT and WM115 cells were 
treated with a Gli inhibitor, GANT58 and a constitutively express-
ing c-Myc T58A plasmid, along with HAS3-EVs. The impact of 
the treatments on proliferation was also tested in both HaCaT (g) 
and WM115 (h) cells. All the statistical significance tests were 
done in comparison to control. The data represent mean ± S.E. of 
four independent experiments. *P value < 0.05, **P value < 0.01, 
***P value < 0.001, one-way ANOVA (Tukey’s test). H3 or H3-EVs 
HAS3-EVs, Clsi and Myci siRNAs for claspin and c-Myc, E-cad 
E-cadherin, Gli-inhi or Gli Gli inhibitor
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Fig. 6  Presence of IHH in HAS3-EVs and feedback between HA and 
HH pathways. a q-PCR showing the RNA expression of HH genes 
in MV3-GFP-HAS3 cells. HA production was induced with doxycy-
clin (Dox) and inhibited with mannose. b HA levels were detected in 
MV3-GFP-HAS3 cells with or without doxycycline and GANT58. c 
Western blots showing expression of IHH, DHH and EGF mitogens 
in MV3- and HAS3-EV lysates. Actin was used as the loading con-
trol. d Western blots showing expression of IHH in EVs collected 
from MV3 parental cells treated with HAS2 + HAS3i cocktail, mock, 
GFP-ΔHAS3 [45] and GFP-HAS3 plasmid. e Effect of EVs collected 
from MV3 parental cells treated with mock, GFP-ΔHAS3 and GFP-
HAS3 plasmid on HA secretion in HaCaT cells. f HA level in HaCaT 
cells after treatment with EVs collected from MV3-GFP-HAS3 
cells treated with IHHi and dox induction (IHHi and IHHi-HAS3 
EVs). HA secretion was normalized on RNA levels. Data represent 
mean ± S.E. of four independent experiments. *P value < 0.05, **P 
value < 0.01, one-way ANOVA (Tukey’s test). C control, Ci control 
siRNA (scrambled siRNA), HAS3 or H3 or H3-EVs HAS3-EVs, 
MV3 (P) EVs EVs from MV3 parental cells, IHHi IHH siRNAs, 
HAS2i + HAS3i HAS2 and HAS3 siRNAs, Mock pcDNA3 vector
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and PTCH1 gene expression to be elevated with HAS3-EVs 
treatment in HaCaT cells (Fig. 3d). Additionally, the GFP-
HAS3 overexpressing MV3 cells were also treated with 
mannose which reduces UDP-GlcNAc (UDP-N-acetyl glu-
cosamine), a substrate used by HAS1-3 to synthesize HA 
[10]. Interestingly, mannose addition with GFP-HAS3 over-
expression effectively reversed the increased expression of 
IHH, DHH, GLI1, PTCH1 and SMO genes (Fig. 6a). Thus, it 
was clear that expression of HH signaling genes was associ-
ated with HA synthesis. To examine the putative relationship 
between HA synthesis and HH signaling, we again utilized 
MV3 cells with GFP-HAS3 overexpression by doxycycline 
induction. Of note, the addition of Gli inhibitor reduced HA 
secretion in the media when GFP-HAS3 expression was 
induced with doxycycline. Gli inhibitor did not influence HA 
secretion in the absence of doxycycline induction (Fig. 6b). 
We then analyzed the protein expression of IHH and DHH in 
MV3- and HAS3-EVs, alongside another well-known mito-
gen, epithelial growth factor (EGF). The results showed that 
HAS3-EVs contain a significantly higher IHH protein level, 
along with EGF, when compared with MV3-EVs. In fact, 
IHH level in HAS3-EVs was even more remarkable than 
EGF. However, DHH protein level was not different between 
the two groups (Fig. 6c). Therefore, we identified IHH to be 
one of the major mitogens present in HAS3-EVs.
We next investigated whether HAS3 presence in plasma 
membrane and HA synthesis are associated with increased 
IHH secretion in EVs. MV3 parental cells were transiently 
transfected with an inactive GFP-ΔHAS3, which contains 
only the first 86 amino acids at N-terminus. Thus, the mutant 
protein cannot synthesize HA due to the absence of catalytic 
domain [45]. GFP-ΔHAS3 transfected cells showed a posi-
tive band near 35 kDa, whereas wildtype GFP-HAS3 was 
seen near 100 kDa in Western blotting (Suppl. Figure 3b). 
HA secretion was also not increased in GFP-ΔHAS3 trans-
fected cells when compared to wildtype GFP-HAS3 group 
(Suppl. Figure  3c, d). Interestingly GFP-ΔHAS3 EVs 
did not show an increase in IHH protein level, unlike the 
wildtype GFP-HAS3 EVs (Fig. 6d). EVs collected from 
the GFP-ΔHAS3 transfected or parental MV3 cells did not 
increase HA secretion in HaCaT cells, when compared to 
cells treated with GFP-HAS3 EVs (Fig. 6e). Also, in MV3 
parental cells, inhibition of endogenous HAS2 and HAS3 
using a cocktail of siRNAs reduced IHH secretion in EVs 
(Fig. 6d). HAS2 and HAS3 inhibition also reduced HA 
secretion in MV3 cells (Suppl. Figure 4b). To further dem-
onstrate the specificity of IHH as a stimulus in HAS3-EVs, 
siRNAs against IHH were used in MV3-GFP-HAS3 cells 
before isolating EVs. HaCaT cells were then treated with 
EVs from MV3-GFP-HAS3 cells with or without IHH siR-
NAs (or IHHi) and HA secretion was analyzed. The results 
showed a significant reduction in HA level in cells treated 
with IHHi-HAS3 EVs compared to cells treated with normal 
GFP-HAS3 EVs (Fig. 6f). This shows that IHH secretion in 
EVs is associated with HA synthesis and the released IHH 
in EVs influence HA synthesis in target cells. We have previ-
ously shown that HAS3 presence in plasma membrane and 
its release in EVs depends on its ability to synthesize HA. 
We have also demonstrated that HA synthesis by HAS3 is 
affected by D216A point mutation on its catalytic domain 
or by altering the availability of its substrates, UDP-GlcUA 
and UDP-GlcNAc using chemicals like 4MU, mannose and 
glucosamine [33, 46]. Though the point mutation was stud-
ied in mHAS3, it is important to pinpoint that there are 97% 
conserved amino acids shared between mHAS3 and human 
HAS3 protein sequences [47]. First, we transfected MV3 
cells with GFP-mHAS3 D216A and treated MV3-HAS3 
cells with 4MU, mannose and glucosamine. EVs were col-
lected and examined for GFP and IHH immunostaining. 
As shown in (Fig. 7a), mHAS3 D216A was not present in 
EVs and did not increase IHH secretion, when compared to 
GFP-HAS3 transfection. While reducing UDP-GlcUA by 
4MU and UDP-GlcNAc by mannose significantly blocked 
GFP-HAS3 presence in EVs, increasing UDP-GlcNAc by 
glucosamine enhanced GFP-HAS3 in EVs (Fig. 7b). IHH 
secretion was also increased in glucosamine treatment with 
GFP-HAS3 group (Fig. 7b). Glucosamine also had an effect 
without GFP-HAS3 overexpression, which could be partially 
explained by the fact that this chemical increases O-Glc-
NAc modification and activation of endogenous HAS3 and 
HAS2 [33, 48]. As the next step, we also analyzed changes 
in HaCaT cell proliferation with MV3-EVs containing GFP-
mHAS3 D216A or GFP-HAS3. The results showed that only 
GFP-HAS3 EVs induced an increase in HaCaT prolifera-
tion (Fig. 7c), which is in line with our earlier observation 
(Fig. 2c). In all these experiments, doxycycline did not show 
any adverse effects (Suppl. Figure 2d–g). The above results 
show that HA synthesis is associated with the release of 
HAS3 and IHH in EVs. In addition, both HA synthesis and 
HH signaling have a positive feedback regulation on each 
other.
As proof of concept, we next wanted to know how claspin 
protein expression, as the downstream effector of HA-IHH-
c-Myc signaling axis, correlates with HA content in different 
stages of cutaneous melanocytic lesions. Immunohistochem-
ical staining indicated that keratinocytes and melanocytic 
cells were positive for intracellular claspin while it was 
almost negative in stroma (Fig. 7d). The staining intensity 
was moderate or weak in dysplastic melanocytic lesions and 
in situ melanomas, while the staining intensity in invasive 
melanomas was negative or weak (Fig. 7e). Interestingly, 
this staining pattern of claspin in different stages of mela-
noma corresponded to HA staining in melanoma progres-
sion as shown before [33, 49]. This suggests that during 
melanomagenesis claspin expression follows changes in HA 
content. Whether or not IHH and c-Myc follows a similar 
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Fig. 7  HA synthesis is associated with IHH secretion in HAS3-EVs. 
a Western blotting analysis of MV3 cells with GFP and GFP-mHAS3 
D216A transfection. MV3 and MV3-GFP cells treated with or with-
out doxycycline were also used as controls. The GFP band for HAS3 
is near ~ 100  kDa while the band for only GFP is near ~ 35  kDa. b 
Western blotting analysis of MV3-HAS3 cells with or without 4MU, 
mannose and glucosamine treatments. Uninduced group was used as 
control. c 96  h HaCaT cell proliferation with or without treatment 
of EVs obtained from the described MV3 cell lines. Data represent 
mean ± S.E. of three independent experiments; **P value < 0.001, 
one-way ANOVA (Tukey’s test). In panels a and c, representative 
blots from 3 independent experiments are shown. d, e Melanoma 
tissue sections were stained to check for claspin immunoexpression, 
scale bar 100  µm. Data represent mean ± S.E. of 3–4 independent 
experiments in (a) and (b) and mean ± S.E. of 12–16 tissue sections 
score in (d). *P value < 0.05, **P value < 0.01, one-way ANOVA 
(Tukey’s test) in (a) and (b)
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pattern of correlation to HA content during melanomagen-
esis remains to be studied in the future.
Discussion
Cutaneous melanoma is one of the deadliest cancers with 
nearly 80% mortality rate. It is a cancer with an aggres-
sive clinical course which has recently been reported 
to have acquired resistance to existing therapies [50]. 
New targets for therapies and the development of new 
biomarkers depends on a better understanding of the 
signaling sequence and the biological events occurring 
in the tumor cells. Tumor cells secrete more EVs than 
normal cells and carry genetic and cellular information 
allowing communication with neighboring cells and the 
tumor microenvironment, either via paracrine or auto-
crine signaling [51]. EMT and pre–metastatic niche for-
mation depend on tumor-derived EVs [2, 52, 53]. In this 
study, we demonstrated that EVs released from HAS3 
overexpressing metastatic melanoma cells (MV3) inter-
acted with keratinocyte (HaCaT) and melanoma (WM115) 
cells and induced proliferation and expression of EMT 
markers, similar to that in tumorigenesis (Fig. 8). HaCaT 
cells were used in this study since their low endogenous 
HA secretion facilitates analyses of transformative changes 
by EVs secreted from a melanoma cell line such as MV3 
with high levels of HA. The MV3 cells released more EVs 
due to HAS3 overexpression and carried HAS3 and HA 
coat on the vesicles. Incubating HaCaT and WM115 cells 
with HAS3-EVs resulted in a higher proliferation rate 
than cells with no treatment, or cells treated with MV3-
EVs. HAS3-EVs increased the expression of c-Myc, an 
oncogenic factor activated in many different cancers types 
[21, 54]. IHH present in HAS3-EVs acted as a stimulus 
upstream to c-Myc and we showed that the signaling axis 
extended to the activation of claspin. The IHH-c-Myc-
claspin axis may help a normal keratinocyte (HaCaT) and 
a melanoma cell line (WM115) to gain tumorigenic poten-
tial, such as increased proliferation; this effect may be due 
Fig. 8  A schematic presentation 
of the mechanisms triggered 
by HAS3-induced EVs in 
target cells. HAS3-EVs from 
melanoma cells are possibly 
interacting with receptors such 
as CD44 present on the surface 
of recipient cells. As shown in 
the figure, direct fusion with 
the plasma membrane and 
endocytosis are also possible 
mechanisms of interaction. IHH 
present in the EVs activates the 
HH signaling cascade in the 
recipient cells, leading to the 
activation of c-Myc and claspin 
expression. This signaling 
cascade leads to an increase in 
proliferation and EMT in the 
recipient cells
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to an enhanced G1/S phase transition and EMT. Since 
c-Myc and hedgehog signaling are independently known to 
increase tumorigenic progression of the cells [21, 27], the 
implicated cross-talk between the two different pathways, 
here acting as one, is of significance (Fig. 8). However, our 
data cannot exclude the possibility that c-Myc and IHH 
could have additional, unknown downstream effectors and 
this possibility remains to be investigated in the future. 
We have also shown that HA synthesis in melanoma cells 
is associated with the release of HAS3 and IHH in EVs 
and there is a positive feedback regulation between HA 
and HH pathways. Thus, we suggest that HA synthesis 
could be one of the stimulating factors for IHH secretion 
in melanoma cells. Future studies should focus on under-
standing the molecular mechanisms behind the feedback 
relationship shared by HA and HH pathways.
As a proto-oncogene, c-Myc plays an important role 
in the pathobiology of numerous cancers including mela-
noma. Being at the crossroads of numerous growth signal-
ing pathways, c-Myc activates the transcription of several 
genes involved in cell growth, among which the E2F fam-
ily of transcription factors have also been reported [55]. 
E2Fs are key factors in cell cycle progression with a direct 
control over cyclins and CDKs [56, 57]. Fernandez et al., 
reported that Myc interacts with E2F promoter and overex-
pression of Myc induces the expression of E2F genes [55, 
58]. E2Fs are known to directly bind to and induce tran-
scription of growth-promoting genes such as DHFR, DNA 
polymerase α, CDC6, ORC1, thymidine kinase, cyclin E, 
cyclin A and numerous other genes relevant for prolifera-
tion and differentiation [59–61]. Our antibody array results 
were complimentary to these findings; we found a twofold 
increase in E2F1 and > 1.5-fold increase in E2F2 in HaCaT 
cells treated with HAS3-EVs (Fig. 3a). Additionally, Cyc-
lin E, CDK1 and the cell proliferation marker Ki67 were 
all increased upon HAS3-EVs treatment. c-Myc has been 
shown to regulate the expression of E2F transcription fac-
tors [55], which in turn regulate promoter activity of claspin 
and chk1 [62]. Our study showed that HAS3-EVs treated 
HaCaT and WM115 cells exhibited high levels of c-Myc 
and claspin and knocking them down decreased the prolif-
eration rate. Furthermore, knocking down c-Myc decreased 
claspin expression while knocking down of claspin did not 
influence c-Myc levels. Bertolli et al., have shown that onco-
genic stimulation causes replication stress, and oppositely, 
sustained E2F-dependent transcription allows the cells to 
decrease replicative stress and remove the block for cell pro-
liferation [63]. During oncogenic transformation, cells could 
utilize claspin, because it helps to circumvent replicative 
stress [64]. However, in this study, we have shown that an 
increase in c-Myc and possibly E2F transcription factors are 
decisive factors in aiding enhanced cell proliferation due to 
IHH stimulus. Claspin plays a role downstream from c-Myc, 
perhaps regulating the replication stress due to increased 
proliferation. Nevertheless, the exact molecular mechanism 
behind claspin’s role remains to be explored.
Although we only investigated hedgehog signaling in 
this study, both hedgehog and MAPK pathways could be 
involved upstream of c-Myc, stimulating HAS3-EVs-medi-
ated target cell proliferation. Crosstalk between MAPK and 
Gli was reported previously [65]. In this study, we observed 
that HAS3-EVs carried IHH and along with it, DHH and 
EGF as well. The high levels of IHH in HAS3-EVs were 
surprising, given that most of the reported studies on mel-
anoma and other cancers have largely implicated the role 
of SHH in the process [66–68]. However, IHH is a well-
known stimulus for self-renewal and enhanced prolifera-
tion in several cancers, including colorectal [69], lung [70], 
pancreatic [71], gastric [72], and T cell acute lymphoblas-
tic leukemia [73]. Our results also point out that knocking 
down IHH in MV3-GFP-HAS3 cells negatively impacts the 
HAS3-EVs ability to enable HA secretion in HaCaT cells 
and downregulation of HAS2 and HAS3 in MV3 parental 
cells decreases IHH secretion in EVs. Thus, IHH could be 
an important mitogen in melanoma progression that has not 
been studied and it is interesting that HA signaling contrib-
utes to this phenomenon. The inhibition of Gli1/2 activity 
and the rescuing of c-Myc by transient transfection of MYC-
T58A [74] demonstrated an involvement of the HH pathway 
in the HAS3-EVs treated cells. Activation of the HH path-
way and increased c-Myc expression not only upregulated 
proliferation but also initiated EMT, which is important for 
cancer metastasis. The role of the HH pathway in EMT is 
well documented in cancer cells undergoing metastasis or 
tumor progression [75–79]. HH pathway signaling has been 
shown to have pathological effects in many cancer types [3]. 
Activation of the HH pathway increases cyclin D1 and B1 
expression leading to an increase in proliferation in basal 
cell carcinoma [80].
Since MV3 is a metastatic melanoma cell line, it was of 
interest to analyze the relationship of HH gene expression 
and HA synthesis. Our results show that both the expres-
sion of HH genes and HAS3-mediated HA synthesis may 
form a positive feedback loop regulation. A similar positive 
feedback regulation between HA and other cancer promoting 
factors, such as ZEB1 [81] and Akt [82], has been identified, 
for example in breast cancer. Gli-1 and Gli-3 were shown to 
bind directly to the HAS2 promoter and regulate its tran-
scription [83]. Although only HAS2 regulation is known 
so far, our results suggest that the HH pathway has a direct 
impact on HA synthesis, possibly by HAS3 regulation. We 
have previously shown that HA content increases in in situ 
melanoma but then declines in more advanced and inva-
sive stages of melanoma, suggesting that HA may be more 
important in the early stages of cancer progression [33, 49]. 
In this work, as an end target of the HA-IHH-c-Myc-claspin 
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signaling cascade, we have found that claspin follows a 
similar tissue staining pattern as HA during melanoma pro-
gression. However, it is unknown whether c-Myc and HH 
pathway factors Gli-1 and 2 also follow the same pattern of 
expression in different stages of melanoma.
About 40–50% of melanoma patients have mutations in 
valine at position 600 (Val600) of BRAF protein, which 
leads to aberrant activation of MAPK pathway [84]. Since 
MEK acts downstream to BRAF in the MAPK pathway, 
a combination of BRAF and MEK inhibitors such as 
vemurafenib, dabrafenib, trametinib and cobimetinib have 
improved the effect of treatment of patients with advanced 
and metastatic melanoma. Other classes of therapeutic drugs 
with improved efficacy that have gained attention in recent 
years are immunotherapeutic drugs such as checkpoint inhib-
itors and oncolytic viruses. Some of these drugs approved 
for advanced stages of melanoma include nivolumab and 
pembrolizumab (PD-1 inhibitors), ipilimumab (anti-CTLA4 
antibody) and the oncolytic virus talimogene laherparepvec 
(TVEC). The increase in progression-free survival for these 
type of immunotherapy ranges from 2.9 to 11.5 months [85]. 
However, the challenge with these targeted therapeutics are 
the adverse effects and failure to improve patient survival to 
a significant extent [86, 87]. Also, almost 50% of patients 
do not respond to the immunotherapy option [85]. This 
demonstrates the urgent need to screen for novel biomark-
ers, to identify and target specific mutations and signaling 
pathways. EVs not only act as biomarkers in this regard but 
can also show how patients respond to a particular treat-
ment. In peripheral blood, a gene signature of 15 differen-
tially expressed genes, which includes MYC and CDK2, is 
predictive and prognostic to anti-CTLA4 immunotherapy 
treatment and 1 year overall survival in melanoma patients 
[88]. Tumor-derived EVs are abundant in plasma [89] and 
some of the differentially expressed genes described above 
could be applicable in melanoma EVs. Another study on 
melanoma patients pinpointed that lymphatic exudates 
contained enriched EVs with tumor-specific markers like 
tetraspanins, ICAM-1, Rab-GTPases and integrins. In fact, 
the tumor-specific markers are more enriched in lymph than 
in plasma, suggestive that lymph could be well suited for 
biomarker analysis in melanoma [90]. BRAF V600E onco-
genic mutation is detected in lymph-derived melanoma EVs, 
and the increase in mutation frequency in patients correlates 
with risk of relapse [91]. These results indicate that EVs can 
be a powerful tool to assess melanoma progression and to 
predict therapy response. As shown in our study, one of the 
mitogens from hedgehog signaling pathway, IHH, is signifi-
cantly enriched in melanoma derived HAS3-EVs. Consider-
ing the fact that HA content increases at the initial stages of 
melanoma [33, 49], and that there is a direct feedback regu-
lation between HA synthesis and hedgehog signaling, one 
could speculate that melanoma EVs with enriched hedgehog 
mitogens like IHH may be a good predictor for the progres-
sion and therapy response at early stages of melanoma. In 
addition, it would be interesting to see if inhibitors of hedge-
hog signaling combined with the available immune thera-
peutics improve the survival of melanoma patients. Since 
HA coated EVs originate from HAS3 expressing cells [10], 
from primary cells such as mesothelial cells [92] and from 
human mesenchymal stem cells [93], their role as messen-
gers in the extracellular space can be acknowledged. As 
shown in this study, HA-coated EVs are associated with the 
release of tumor promoting IHH mitogen from melanoma 
and these EVs could influence its surrounding microenviron-
ment to melanoma progression. Future studies should focus 
on the mechanistic details on how HA synthesis mediates the 
release of IHH in EVs and how the secreted IHH promotes 
melanoma progression.
Materials and methods
Cell lines and culture conditions
MV3 parental cells, and the MV3 and C8161 cells stably 
overexpressing doxycycline-inducible GFP-HAS3 [32], 
the MV3 cells stably overexpressing GFP (MV3-GFP) and 
WM115 cells were cultured in DMEM medium with high 
glucose (4500 mg/l) (Euroclone, Milan, Italy). HaCaT cells 
were cultured in DMEM with low glucose (1000 mg/l) 
(Sigma-Aldrich, USA). All cells were supplemented with 
inactivated 10% fetal bovine serum (FBS) (HyClone, 
Thermo Scientific, Epsom, UK), 4 mM l-glutamine (Sigma-
Aldrich, USA), 50 µg/ml streptomycin sulfate and 50 units/
ml penicillin (Sigma-Aldrich, USA). The MV3 stable cell 
line was maintained in 50 µg/ml hygromycin and it was 
induced with 0.25 µg/ml doxycycline during experiments. 
To check the adverse effects of doxycycline on EV secretion 
and hyaluronan synthesis, MV3 and MV3-GFP cells were 
used (Suppl. Figure 2d–g).
EV-depleted FBS used for EV isolation experiments was 
prepared by ultracentrifugation at 110,000 × g for 16 h fol-
lowed by sterile filtering with 0.22 µm filters (Minsart, Sar-
torius, Stedim, Biotech, Goettingen, Germany).
EV isolation
MV3 and C8161 cells (3.2 × 106) were plated in 15 cm cell 
culture dishes and incubated for 24 h to reach 50% con-
fluency. The complete media was replaced with EV-free 
media (16 ml/dish) and collected after 48 h of incubation. 
To remove cell debris, the media was centrifuged at 1000 × g 
for 10 min at 4° C. Next, the supernatant was transferred into 
new tubes and centrifuged at 1200 × g for 20 min at 4° C. 
Finally, the supernatant was ultra-centrifuged at 110.000 × g 
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for 90 min at 4° C and the pellet was dissolved in PBS (ster-
ile filtered in 0.22 µM filter). The EV preparations were 
stored at − 80° C.
EVs isolated from MV3 cells stably overexpressing dox-
ycycline-inducible GFP-HAS3 without dox induction are 
called as “MV3-EVs” and EVs collected after doxycycline 
induction are called as “HAS3-EVs”. EVs isolated from 
C8161 cells stably overexpressing doxycycline-inducible 
GFP-HAS3 without dox induction are called as “C8161-
EVs” and EVs collected after doxycycline induction are 
called as “C8161-HAS3 EVs”. EVs isolated from parental 
melanoma MV3 cells are called as “MV3 parental EVs”. 
EVs isolated from cells after siRNA treatments for IHH are 
called as “IHHi EVs” and the same with dox induction are 
labelled as “IHHi-HAS3 EVs”. Similarly, EVs isolated from 
cells with the siRNA cocktail against HAS2 and HAS3 are 
called as “HAS2 + 3i EVs”. EVs isolated from MV3 cells 
with transient transfection of GFP-ΔHAS3 are called as 
“ΔHAS3 EVs”. The nomenclature is explained in the table 
(Table 1).
Nanoparticle tracking analysis
The concentration and size distribution of EVs collected 
from MV3 cells were analyzed using a Nanoparticle Track-
ing analyzer (NTA) (Malvern Instruments Ltd., Malvern, 
UK) with an NS300 view unit. The settings used for data 
acquisition were as follows: camera level 13, acquisition 
time 30 s and detection threshold 3, kept constant during 
measurements. Analysis was done using the NTA 3.1 soft-
ware (Nanosight, Amesbury, UK).
Transfection
For transfections, cells were seeded in a 12 well plate 
(HaCaT: 11 × 104 cells/well, WM115: 16 × 104 cells/well, 
MV3: 1.1 × 104), 6 cm dishes (HaCaT: 7 × 105 cells/dish, 
WM115: 1.1 × 106  cells/dish) and 15 cm dishes (MV3: 
3 × 106 cells/dish, MV3-GFP HAS3: 3.2  × 106 cells/dish). 
Once they reached 40–50% confluency, they were trans-
fected with plasmid DNA or siRNAs.
Plasmid transfection was done with Lipofectamine 3000 
(Invitrogen) and siRNA transfections were done with Lipo-
fectamine RNAiMAX (Invitrogen), according to the man-
ufacturers’ instructions. c-Myc T58A (Addgene, USA), 
EGFP-C1 (Clontech, USA), pcDNA, GFP-mHAS3 D216A 
[46] and GFP-ΔHAS3 plasmids were used in 12 well, 6 cm 
and 15 cm plate formats. Predesigned siRNAs targeting 
claspin: siRNA-1 (60 nM) (ID: s34330), siRNA-2 (60 nM) 
(ID: s34332), c-Myc: siRNA-1 (HaCaT: 30 nM, WM115: 
60 nM) (ID: s9130), siRNA-2 (HaCaT: 30 nM, WM115: 
60  nM) (ID: s9131), IHH: siRNA-1(MV3-GFP HAS3: 
50 nM) (ID: s7257), siRNA-2 (MV3-GFP HAS3: 50 nM) 
(ID: s7258), HAS2: siRNA-1 (MV3: 50 nM) (ID: s6457), 
siRNA-2 (MV3: 50 nM) (ID: s6459) and HAS3: siRNA-1 
(MV3-GFP HAS3: 50 nM) (ID: s194495), siRNA-2 (MV3-
GFP HAS3: 50  nM) (ID: s6460) were purchased from 
Ambion, Thermo Fisher Scientific Waltham, MA, USA. 
Scrambled (control) siRNA (30 nM) from Origene (ref no: 
SR30004) was used. The cell media containing the transfec-
tion mix was removed after 24 h and the cells were either 
treated with EVs for 24 h or re-plated for proliferation or 
treated for 48 h with EV-free serum media for collecting 
EVs.
Treatments
Both MV3- and HAS3-EVs were diluted to a standard 
200 µg/ml protein concentration in PBS. MV3- and HAS3-
EVs were added to the target cells for treatment using a cal-
culation of 120 µg protein to a seeding density of 0.3 × 106 
cells, for example in a 6-well growth area. For culture plates 
with higher growth area, the amount of EVs were calculated 
according to the corresponding seeding density i.e. 320 µg 
for 6 cm dish with 0.8 × 106 seeded cells and 0.8 mg for 
10 cm dish with 2.0 × 106 seeded cells. The final concentra-
tion for Gli inhibitor, GANT58 (Sigma-Aldrich, USA) was 
10 µM in HaCaT cells, 1 µM in WM115 cells and 5 µM in 
Table 1  Nomenclature of 
different types of EVs and cell 
lines used in this study
Cell line Treatment Collected EVs and 
their nomenclature
MV3-GFP-HAS3 No dox induction MV3 EVs
MV3-GFP-HAS3 dox induction HAS3 EVs
C8161-GFP-HAS3 No dox induction C8161 EVs
C8161-GFP-HAS3 dox induction C8161 HAS3 EVs
MV3 parental No treatment MV3 (P) EVs
MV3 parental GFP-ΔHAS3 transfection ΔHAS3 EVs
MV3 parental HAS2 + 3i transfection HAS2 + 3i EVs
MV3-GFP-HAS3 IHHi transfection IHHi EVs
MV3-GFP-HAS3 IHHi transfection and dox induction IHHi-HAS3 EVs
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MV3 EGFP HAS3 cells. In some experiments, 1 mM Glu-
cosamine (Sigma), 20 mM Mannose (Sigma,) and 0.5 mM 
4MU (Sigma) were used. HaCaT cells were treated with 
hyaluronan oligosaccharides of various lengths (HA6, HA8 
and HA10 (Seikagaku Kogyo Co., Tokyo, Japan) at a final 
concentration of 0.1, 0.2 and 0.5 mg/ml.
Transmission electron microscopy (TEM)
The EV preparations (10 µl) isolated from MV3 cell culture 
media were layered onto carbon-coated glow-discharged 
nickel grids (Agar Scientific Ltd, Sanstedt, UK). Grids were 
fixed in 2% paraformaldehyde for 10 min, contrasted using 
2% neutral uranyl acetate (UA) for 10–15 min in the dark 
and embedded in 1.8% methyl cellulose (25 Ctp)/0.4% UA. 
Samples were imaged using a JEOL JEM 2100F transmis-
sion electron microscope (Jeol Ltd, Tokyo, Japan) operated 
at 200 kV.
Confocal microscopy
Fluorescent images were taken with 40 × (NA 1.3) and 
63 × (NA 1.4) oil objectives on a Zeiss Axio Observer 
equipped with a Zeiss LSM 700 confocal module (Carl Zeiss 
Microimaging GmBH, Jena, Germany) and a Zeiss XL-LSM 
S1 incubator with temperature and  CO2 control. ZEN soft-
ware (Carl Zeiss Microimaging GmBH) was used for image 
processing and 3D rendering.
Cell lysis and Western blotting
Cells (HaCaT and WM115) grown in 6 cm dishes were 
treated with EVs for 24 h and lysed using NE-PER™ kit 
(Thermo Scientific) to isolate nuclear and cytoplasmic frac-
tions. Protein content was determined using a Pierce BCA 
protein assay kit (Thermo Scientific, Epsom, UK). The 
proteins in the cell fractions were separated using a 10% 
SDS-PAGE and transferred to nitrocellulose membranes 
(Protran, Whatman), blocked with 5% bovine serum albu-
min (BSA) in Tris buffered saline containing 0.1% Tween 
20 (TBST) or 5% skimmed milk-TBST for 1 h at room tem-
perature and then incubated overnight with anti-claspin 
(1:2000, 5% BSA-TBST) (Proteintech, USA), anti-c-Myc 
(1:500, 5% BSA-TBST) (Santa Cruz, USA), anti-CD63 
(1:1000, 5% BSA-TBST) (Abcam, UK), anti-Actin (1:2000, 
5% milk-TBST) (Santa Cruz), anti-lamin β1 (1:2000, 5% 
milk-TBST) (Abcam), anti-Gli1 (1:1000, 5% BSA-TBST) 
(Abcam), anti-Gli2 (1:1000, 5% BSA-TBST) (Proteintech), 
anti-DHH (1:1000, 5% BSA-TBST) (Abcam), anti-IHH 
(1:1000, 5% BSA-TBST) (Abcam), anti-MAPK p42/44 
(1:1000, 2% BSA-TBST) (Cell Signaling), anti-NFκB p65 
(1:200, 1% BSA-TBST) (Santa Cruz), anti-EGFR (1:1000, 
5% BSA-TBST) (Cell Signaling), anti-CD44 (1:2000, 1% 
BSA-TBST) (Chemicon, Temecula, CA), anti-EGF (1:1000, 
5% BSA-TBST) (Abcam), anti-GFP (1:2000, 5% BSA-
TBST) (Invitrogen) and anti-Calnexin (1:2000, 5% BSA-
TBST) (Cell Signaling). Alexa-Fluor plus 555 anti-mouse 
or Alexa-Fluor plus 680 anti-rabbit secondary antibodies in 
2% milk-TBST (1:10,000 dilution) (Thermo Scientific) were 
used. The membranes were washed three times for 5 min 
with TBST after antibody incubations and visualized using 
a BioRad ChemiDoc scanner.
RNA isolation and q‑PCR
The cells were lysed using NucleoZOL (Macherey–Nagel, 
Germany) and RNA extraction was done according to 
the manufacturer’s instructions. For q-PCR, the primer 
sequences used are mentioned in supplementary Table 2. 
Roche FastStart Universal SYBR Master mix was used. 
Relative mRNA levels were calculated according to 
2^(− ΔΔCT) method with GAPDH used as the housekeep-
ing gene.
Hyaluronan assay
MV3-GFP-HAS3 cells grown in six-well plates 
(2 × 105 cells/well) were induced with doxycycline (0.25 µg/
ml). 24 h post seeding, the cells were treated with mannose 
or GANT58 for 6 h. The growth medium was then collected 
and stored at − 20 °C. Culture medium was also collected 
from 1 × 105 HaCaT cells grown in 12 well plate, treated 
with MV3- or HAS3-EVs for 24 h. The cells were then lysed 
using NucleoZOL (Macherey–Nagel, Germany) and RNA 
extraction was carried out. In some cases, cell numbers were 
also counted. The HA content in the culture medium was 
analyzed using a previously established enzyme-linked sorb-
ent assay [94]. The HA content was normalized to RNA 
concentration.
RNA sequencing and data analysis
HaCaT cells were grown in six well plates (4.5 × 105 cells/
well) and treated with MV3- and HAS3-EVs for 24 h. Cells 
were lysed, and RNA was extracted using a high pure RNA 
isolation kit (Roche). The isolated RNA samples (N = 3 
per group) were then sent for RNA-seq library generation 
(Illumina TruSeq stranded mRNA library preparation kit) 
and single-end sequencing using Illumina Hi seq (Illumina 
HiSeq 3000 instrument) at the Finnish Functional Genomics 
Centre, Turku center for biotechnology (Finland).
The 50 nt RNA-seq reads were quality controlled using 
FastQC (version 0.10.1) and trimmed with Trimmomatic 
(version 0.33) [95] using long TruSeq 3-SE.v2 adapters 
with the essential settings: ILLUMINACLIP:0:30:10, 
LEADING:3, TRAILING:3, MINLEN:35. Trimmed reads 
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originating from mitochondrial DNA or ribosomal RNA, 
or composed of a single nucleotide, were then removed 
using bowtie2 (version 2.2.3) [96]. The remaining reads 
were aligned to the Gencode human transcriptome version 
24 basic (for genome version hg38) using Tophap2 (ver-
sion 2.0.13) [97] with essential non-default settings: read-
gap-length 1, segment-mismatches 1, library-type fr-first 
strand, coverage-search, prefilter-multihits. The initial, 
unprocessed read counts ranged from 16.1 to 21.7 million 
per sample, out of which 11.6–17.1 million survived pre-
processing and were aligned. All samples had very high 
mean Sanger 1.9 encoded sequence quality scores (> 39). 
Gene-wise read counts were collected in R (version 3.3.2) 
using GenomicAlignments:summarizeOverlaps (version 
1.10.1) and, after normalization using variance stabilizing 
transformation (vst), they were subjected to sample-level 
quality control: no batch effects were identified. To iden-
tify differentially expressed genes between experimental 
groups, gene-wise read counts were analyzed in R (version 
3.4.1) using DESeq 2 (version 1.16.1), employing Wald 
statistics and FC shrinkage [98].
Sample preparation for proteomics
HaCaT cells grown in 6 cm dishes were treated with  (7x105 
cells/dish) MV3- and HAS3-EVs for 24 h. Along with 
HAS3-EVs, c-Myc inhibitor was also added to the cells 
with appropriate control samples. The cells were lysed 
using RIPA buffer (with protease inhibitor cocktail) (Sigma-
Aldrich). 10 µg of total protein amounts were digested using 
a modified FASP protocol, as previously reported [99] .
Liquid chromatography high‑definition tandem 
mass spectrometry
The samples were analyzed in a randomized order. 300 ng 
of digested proteins/replicate (three technical replicates 
per sample) were used in nano-LC-HD-MSE analysis. The 
nano-LC-HD-MSE analyses were executed as described 
[100, 101]. Database searches were carried out against 
UniProtKB/Swiss-Prot reviewed human database (release 
2017.10.03 with 20,239 entries) with the Ion Accounting 
algorithm and using the following parameters: peptide and 
fragment tolerance, automatic; maximum protein mass, 
750 kDa; minimum fragment ions matches per protein, ≥ 7; 
minimum fragment ions matches per peptide, ≥ 3; minimum 
unique peptide matches per protein, ≥ 2; primary digest rea-
gent as trypsin; missed cleavages allowed, 2; fixed modi-
fication, carbamidomethylation C; variable modifications, 
deamidation (N, Q) and oxidation of methionine (M); and 
false discovery rate < 4%.
Bioinformatic analyses
For differential expression analysis (defining differentially 
expressed proteins, DEPs), the list was limited to those 
quantified with a fold change (FC), FC > 1.5 and P ≤ 0.05 
by analysis of variance for all comparisons. The list of up/
downregulated protein changes with their corresponding 
unique UniProtKB/Swiss-Prot identifiers served as inputs 
into  Ingenuity® Pathway Analysis (IPA) bioinformatics anal-
yses (Qiagen Bioinformatics, Redwood City, CA, USA) and 
screened for associated canonical pathways. The identified/
quantified proteins with their respective relative abundance 
protein ratios are reported in supplementary Table 1.
Cell proliferation
4 × 104 cells/well of HaCaT and 6 × 104 cells/well of WM115 
were added to a 12 well plate and treated with EVs. During 
the EV treatment, cells were grown in 5% EV free serum 
media. The cells were then harvested and counted for a 
period of 4 days. During treatment with siRNAs, plasmids 
and inhibitors, the cells were incubated with EVs for an 
additional 2 days. At the end of 2 days, they were trypsi-
nized and counted.
Type I collagen 96 well plate invasion assay
Cells were treated with EVs for 24 h and plated as 5 × 104/
well on a pre-coated 96 well plate with type I collagen, as 
per manufacturer’s instructions (#3457-096-K, R&D Sys-
tems, MN 55413, USA). 24 h later, invading cells were 
stained with Calcein-AM in cell dissociation buffer and the 
resulting fluorescence was measured at 488 nm in a plate 
reader.
Cell cycle array
A high throughput ELISA based antibody array (Full moon 
biosystems, California, USA) was used to check the expres-
sion levels of cell cycle proteins (six replicates each) after 
treatment with EVs. HaCaT cells grown in 6 cm dishes were 
lysed using RIPA buffer, treated and the resulting lysates 
were added to the antibody arrays according to the manufac-
turer’s protocol. The protein expression levels were quanti-
fied by Full moon biosystems services.
Tissue staining
The specimens including 14 benign nevi, 15 dysplastic 
nevi, 12 in situ melanomas and 16 invasive melanomas 
were obtained from the archives of the Kuopio University 
Hospital under the ethical approval of Kuopio University 
Hospital and The Finnish National Supervisory Authority 
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for Welfare and Health (VALVIRA). For claspin immuno-
histochemical staining, 5 µm thick formalin-fixed and par-
affin-embedded samples were dewaxed and rehydrated. For 
antigen retrieval, specimens were incubated in 10 mM citrate 
buffer, pH 6.0 for 10 min at 120 °C in a pressure cooker 
and then cooled for 15 min. Endogenous peroxidase was 
blocked with 1% hydrogen peroxide and unspecific staining 
with 2% milk powder in 0.1 M phosphate buffer. There-
after, the sections were incubated with claspin polyclonal 
antibody (Proteintech Antibodies, 23206-1-AP) in a humid-
ity chamber at + 4 °C overnight. The primary antibody was 
used at 1:600. Thereafter, the samples were incubated with 
biotinylated anti-rabbit secondary antibody (1:300, Vector 
laboratories, Burlingame, CA, USA) at room temperature 
for 1 h, followed by incubation with the ABC reagent. 3, 
3′-diaminobenzidine (DAB) was used as a chromogen to 
visualize the staining and the nuclei were counterstained 
with Mayer’s hematoxylin. Finally, the samples were dehy-
drated and mounted in Depex. The stainings were viewed 
with an Axio Lab.A1 microscope (Carl Zeiss, Microscopy 
GmbH, Jena, Germany) and the intensities of the claspin 
staining’s were estimated as follows: negative (0), weak (1), 
moderate (2) or strong (3).
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